Oppenheimer lowered the firm’s price target on Evolent Health (EVH) to $12 from $18 and keeps an Outperform rating on the shares following quarterly results. Management provided visibility into 2026 revenue of $2.5B, which reflects $550M of new contract impact. Though the company continues to boast an attractive pipeline of growth, the near-term outlook remains subjected to the uncertainty around Medicare Advantage and the ACA, adds Oppenheimer.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $11 from $13 at Citizens JMP
- Evolent Health Inc. Reports Strong Q3 Earnings and Strategic Growth
- Evolent Health’s Strong Q3 Performance and Future Growth Potential Underpin Buy Recommendation
- Evolent Health Reports Strong Q3 2025 Results
- Evolent Health: Strategic Growth Potential Amidst Near-Term Challenges